Newsquawk Logo

Bayer’s (BAYN GY) Asundexian demonstrated a 26% reduction in stroke following non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase in ISTH major bleeding compared with placebo”

Bayer's Asundexian data showing a 26% reduction in stroke risk without a corresponding increase in major bleeding suggests a significant advancement in their product pipeline.

Newsquawk StaffPublished On the live feed at — 3 more headlines followed before this page went public
Newsquawk headlinesUTC

BoC Governor Macklem says restructuring the Canadian economy to cope with US tariffs, slower population, and the rise of AI will take years, and could be very painful

Meta (META) said to test standalone app for its Vibes videos, TechCrunch reports

Bayer’s (BAYN GY) Asundexian demonstrated a 26% reduction in stroke following non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase in ISTH major bleeding compared with placebo”

Stellantis (STLAM IM/STLAP FP) says holding more chip inventory after Nexperia situation

US House Republicans issue a subpoena to Coupang (CPNG); seeks documents between Coupang and Korean government, testimony before committee

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

This positive outcome could enhance Bayer's competitive position in the pharmaceuticals sector, potentially boosting investor sentiment and supporting the stock price, especially if the market views this as a catalyst for future sales growth.

External

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.